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Significant relationships between the psychological status and poor asthma outcomes
are often reported. However, most of these studies are cross-sectional and none
have evaluated how the psychological status progresses over time during the
management of asthma patients. Therefore, we examined the longitudinal changes in
the psychological status of asthma patients, and compared them with changes in other
clinical measurements.
Eighty-seven outpatients with stable asthma after 6 months of treatment were enrolled in
this study. The psychological status was evaluated using the Hospital Anxiety and
Depression Scale (HADS), the health status using the Asthma Quality of Life Questionnaire
(AQLQ) and the St. George’s Respiratory Questionnaire (SGRQ). The patient’s pulmonary
function, peak expiratory flow values and airway hyperresponsiveness were measured at
entry and every year thereafter over a 5-year period.
Using mixed effects models to estimate the slopes, the HADS anxiety and depression scores
did not change significantly over time (p ¼ 0.71 and 0.72, respectively). The changes in
the HADS scores correlated noticeably with changes in the AQLQ and SGRQ scores, but not
with changes in the physiological measurements. The baseline HADS anxiety and
depression scores were significantly correlated to the subsequent annual changes in each
measurement.
The psychological status remained clinically stable over the 5-year study period in patients
with stable asthma. Changes in the psychological status were significantly correlated toElsevier Ltd. All rights reserved.
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T. Oga et al.2134changes in the health status. The baseline HADS scores were a useful indicator in detecting
patients who would show subsequent deterioration in their psychological status.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Psychological disturbances such as anxiety or depression are
important features of asthma, because many patients with
chronic disorders are generally at risk for mental disorders.
These mental disorders are associated with poor asthma
outcomes such as worse asthma control and impaired health
status,1 frequent utilization of emergency and hospital
admissions,2 more asthma symptoms,3 higher dosing of
corticosteroids,4 medication non-adherence,5 a worsening
of chronic inflammation,5 or even death.6 Therefore, like
physiological indices such as airflow limitation or airway
hyperresponsiveness (AHR), the psychological components
should also be monitored closely. However, most of the
research on these psychological components is limited to
cross-sectional studies.
Long-term pharmacological treatment consisting of in-
haled corticosteroids is recommended in the management of
asthma. Although many studies covering the clinical course
of asthma have focused mainly on changes in physiological
outcomes such as airflow limitation, changes in outcomes
from the patient’s viewpoint have rarely been reported. To
capture the overall management of chronic asthma, patient
reported outcomes as well as conventional physiological
outcomes should be followed simultaneously. However, to
our knowledge, the longitudinal course of the psychological
status of asthmatic patients has not been investigated.
When analyzing longitudinal data on the psychological
status, analyzing dropouts becomes a problem. The exclu-
sion of dropout data can cause some bias in calculating
slopes for the changes, since the psychological status may
affect patient withdrawal from the study. Therefore, data
analyses that include both completers and dropouts are
important, and we have attempted to do so in our
longitudinal studies of patients with asthma7,8 and chronic
obstructive pulmonary disease (COPD).9–11
We previously recruited outpatients with stable asthma
and followed the longitudinal changes in their physiological
outcomes and patient reported outcomes over a 5-year
period, and partially reported the changes elsewhere
regarding the health status as compared to changes in
airflow limitation, AHR and peak expiratory flow (PEF)
variability.8 In the present observational study, we reviewed
the data and attempted to analyze longitudinal changes in
the psychological status of patients with asthma, and
compared them with changes in other outcomes.Methods
Subjects
We recruited 87 consecutive outpatients with stable
asthma, as previously reported.8 The entry criteria in-
cluded: (1) meeting the definition of asthma by theAmerican Thoracic Society (ATS)12; (2) confirmation of an
over 20% improvement in force expiratory volume in 1 s
(FEV1) or PEF values after the inhalation of b2-agonists
(salbutamol 200 mg); (3) regular attendance and treatment
for asthma over 6 months; (4) a best ratio of FEV1 to forced
vital capacity of more than 0.7 when a subject had a
smoking history to exclude COPD; (5) no other co-morbid-
ities likely to affect changes in any clinical parameters;
(6) no exacerbations over the preceding 4 weeks; and (7) no
changes in treatment within 4 weeks. All clinical measure-
ments were evaluated on the same day. Eligible patients
meeting the entry criteria were asked to have their clinical
outcomes and smoking status evaluated at entry, and every
year thereafter over a 5-year period. The present study
was performed as part of our standard outpatient treatment
and care.
All patients had their PEF monitored regularly, and had
undergone stepwise treatment with inhaled beclometha-
sone dipropionate or fluticasone propionate for their asthma
according to the guidelines proposed by the Global Initiative
for Asthma,13 because long-acting b2-agonists had not been
available in Japan during the study. Furthermore, the
changes in the therapeutic regimen have been reported
elsewhere.8 When an exacerbation of asthma requiring a
change in treatment occurred within 4 weeks of a reassess-
ment, the evaluation was postponed for at least 4 weeks
until the patient had stabilized.Outcome measurements
The psychological status was evaluated using the Japanese
version of the Hospital Anxiety and Depression Scale
(HADS),11,14 which consists of 14 items, seven for anxiety
and seven for depression. Each item is scored from 0 to 3,
where a score of 3 represents a state corresponding to the
worst anxiety or depression. The sum of these items
produces two subscales ranging from 0 to 21. Values on
the HADS of 7 or less were regarded as normal, 8–10 as
indicating a possible abnormality, and values of 11 or more
as being abnormal.14 An increase in the score indicates a
worsening of the psychological status.
The health status was assessed by the Japanese versions
of the Asthma Quality of Life Questionnaire (AQLQ)8,15 and
the St. George’s Respiratory Questionnaire (SGRQ).8,16 The
AQLQ consists of 32 items composed of four domains:
symptoms, activity limitations, emotional function, and
exposure to environmental stimuli. The patients were asked
to recall their experiences during the previous 2 weeks and
to respond to each item using a 7-point interval scale
ranging from 1 (maximal impairment) to 7 (no impairment).
The overall score of the AQLQ was calculated as the mean of
the sum of all items. A decrease in the score indicates a
worsening of the health status. The SGRQ consists of 50
items composed of three components: symptoms, activity
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component items. SGRQ scores range from 0 to 100, with
zero indicating the best health and 100 indicating the worst
health. An increase in the score indicates a worsening of the
health status.
All subjects underwent spirometric testing three times
according to the method recommended by the ATS,17 using a
spirometer (AUTOSPIRO AS-600, Minato Medical Science Co.
Ltd., Osaka, Japan). The highest FEV1 values were then
analyzed. The predicted values were those based on the
Japan Society of Chest Diseases.18
The subjects were asked to measure their PEF three times
before inhaling corticosteroids, and then the highest value
was recorded. PEF variability was assessed as the average of
the amplitude without bronchodilators, percent highest.8,19
AHR was evaluated by the method proposed by Chai
et al.,20 as described in detail elsewhere.7,8 Briefly,
methacholine solutions at different concentrations were
delivered by a dosimeter (Rosenthal French, Baltimore, USA)
using a No. 646 DeVilbiss nebulizer driven by compressed air.
The procedure was stopped when FEV1 fell by more than 20%
from the baseline measured after saline inhalation, or when
the maximal methacholine solution was reached. The results
were expressed as the doses of methacholine (one inhalation
of 1mg/ml methacholine solution ¼ 1 cumulative units
(c.u.)) required to produce a 20% fall in FEV1 (PD20FEV1).
When FEV1 did not decrease by 20% after the inhalation of
the maximal methacholine concentration, a value of its
solution (25mg/ml) was used for the analysis. Various
PD20FEV1 values were determined by linear interpolation
of the log cumulative dose–response curve.
Statistical analyses
The results are expressed as means7SE. Mixed effects
models for the slopes were used to estimate the longitudinal
changes in clinical parameters using SAS (Statistical Analysis
System) PROC MIXED software.21 We used this approach
based on the assumption that the missing data were
considered to be missing at random (MAR). By performing
these analyses, all of the data from the 87 patients with
asthma entered into the present study were included. In this
analysis, the covariates included baseline age, gender,
smoking status and asthma severity based on the percentage
of the predicted FEV1 (%FEV1) as fixed effects, and time was
entered as a random effect.8 Bivariate relationships
between the slope changes were analyzed by Pearson’sTable 1 Baseline data and annual changes in 87 patients with
Characteristic Baseline data
HADS anxiety (0–21) 3.470.3
HADS depression (0–21) 3.370.3
AQLQ overall (1–7) 6.4170.07
SGRQ total (0–100) 20.371.4
FEV1, L 2.2570.09
%FEV1, %predicted 81.771.9
PEF variability 5.770.5
Log(PD20FEV1), c.u. 1.5770.07
The data are presented as means7SE. The numbers in parenthesescorrelation coefficient tests. Relationships between the
baseline HADS scores and their changes were analyzed by
Spearman’s correlation coefficient tests. A p value of less
than 0.05 was considered to be statistically significant.Results
The baseline characteristics for the 87 patients (44 males)
with stable asthma are presented in Table 1. The average
age was 5072 years. Twenty-three patients (26%) had never
been smokers, 46 (53%) were former smokers, and 18 (21%)
were current smokers. Regarding the severity of FEV1, 46
patients (53%) were mild (more than 80% predicted), 31
(36%) were moderate (60–80% predicted), and 10 (11%) were
severe (less than 60% predicted). The anxiety and depression
baseline HADS scores were 3.470.3 and 3.370.3, respec-
tively. Changes in the severity of anxiety and depression
based on HADS scores over 5 years are presented in Table 2.
The number of patients with an abnormal or possible
abnormal psychological status remained unchanged over
time, although the missing data increased over time.
The results from the mixed effects models for the slopes
of longitudinal changes in clinical markers are presented in
Table 1. The annual changes in the HADS anxiety and
depression scores in the 87 patients with asthma were
0.0470.11 and 0.0370.09 units/year, respectively, and
these values were far from statistically significant levels
(p ¼ 0.71 and 0.72, respectively). Changes in the HADS
anxiety and depression scores over 5 years are presented
in Fig. 1.
Regarding the health status, although the overall score of
the AQLQ showed a statistically significant decline
(p ¼ 0.0091), its mean decline rate of 0.06 units/year did
not reach the 0.5 units of the minimum clinically important
difference on the AQLQ22 over 5 years. Regarding the SGRQ,
the total score did not show any statistically significant
changes. With regard to the physiological measurements,
FEV1 and %FEV1 declined slowly but significantly (po0.0001
and 0.0014, respectively). In contrast, the PEF variability
and Log(PD20FEV1) values improved significantly over time
(p ¼ 0.0068 and po0.0001, respectively).
Table 3 shows the relationships between the changes in
HADS scores and other clinical markers. The changes in
the anxiety score of the HADS were significantly correlated
to changes in the AQLQ overall and SGRQ total
scores (r ¼ 0.60, po0.0001; and r ¼ 0.58, po0.0001).asthma.
Annual change (/year) p-Value
0.0470.11 0.71
0.0370.09 0.72
0.0670.02 0.0091
0.370.5 0.54
0.05370.011 o0.0001
1.170.3 0.0014
0.470.2 0.0068
0.0770.02 o0.0001
indicate the theoretical score range. c.u., cumulative units.
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Table 2 Changes in the anxiety/depression severity and missing data in 87 patients with asthma.
HADS score Baseline 1 year 2 year 3 year 4 year 5 year
11p: abnormal 3/0 1/0 1/1 1/2 3/0 1/0
8–10: possible abnormal 3/7 7/6 7/6 5/5 5/7 4/8
7X: normal 81/80 75/77 59/60 54/53 50/51 54/51
Missing data 0 4 20 27 29 28
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Figure 1 Changes in the HADS anxiety scores (a) and
depression scores (b) in patients with asthma. The numbers at
each assessment indicate the number of patients for whom
measurements were available at each time point.
Table 3 Correlation coefficients between changes in
the HADS and other variables.
Variables HADS anxiety HADS depression
AQLQ overall 0.60 0.50
SGRQ total 0.58 0.54
%FEV1 0.10 0.19
PEF variability 0.06 0.15
Log(PD20FEV1) 0.04 0.05
Asterisks indicate statistically significant relationships
(po0.001).
T. Oga et al.2136The changes in the depression score of the HADS were also
significantly correlated to changes in the AQLQ overall and
SGRQ total scores (r ¼ 0.50, po0.0001; and r ¼ 0.54,po0.0001). However, the changes in the HADS did not
correlate significantly with the changes in %FEV1, PEF
variability and Log(PD20FEV1).
There were significant positive relationships between the
baseline HADS scores and their subsequent changes in both
anxiety (Rs ¼ 0.62, po0.0001) and depression (Rs ¼ 0.53,
po0.0001) subscales. Furthermore, a strong relationship
was observed between the changes in the anxiety scores and
the changes in the depression scores (r ¼ 0.77, po0.0001).
In addition, in order to confirm if the baseline data could
predict subsequent changes, we arbitrarily divided the
patients into three groups based on their baseline score:
Group I (HADS scores: 0–2), Group II (3–5) and Group III
(more than 6). In the anxiety score of the HADS, 37, 27 and
23 patients were classified into Groups I, II and III,
respectively, and their annual changes were 0.3670.04,
0.0870.08 and 0.5270.14 units/year. In the depression
score of the HADS, 42, 25 and 20 patients were classified
into Groups I, II and III, respectively, and their annual
changes were 0.2270.05, 0.1870.09 and 0.4070.11
units/year. These findings indicated that the higher the
HADS scores were at baseline, the faster their deteriorations
were.Discussion
We demonstrated that, with maintenance therapies con-
sisting of inhaled corticosteroids, the psychological status as
evaluated by the HADS remained clinically stable for 5 years
in patients with stable asthma after 6 months of treatment.
To our knowledge, this is the first study to analyze
longitudinal changes in the psychological status of stable
asthmatic patients. In addition, these changes in the
psychological status correlated significantly with changes
in the health status, but not with changes in the
physiological measurements. The baseline psychological
status was a significant predictor of subsequent changes,
even when they were initially within the normal range.
We showed that the anxiety and depression scores
evaluated by the HADS did not significantly change over 5
years in patients with stable asthma. In the same subject
group, we previously showed that there was a time
difference in the longitudinal changes among patient
reported versus physiological outcomes; in other words,
while the health status was maintained over 5 years, airflow
limitation worsened slowly and PEF variability and AHR
improved.8 The present study shows that current guideline-
based asthma management consisting of inhaled corticos-
teroids can stably maintain patient reported outcomes for
the psychological status as well as the health status, and the
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stability of these indices over time.
Assessing the psychological status is recommended as it is
seemingly related to many poor asthma outcomes.1–6 In
addition, in managing patients with asthma, although the
frequency of reported symptoms is important when changing
the treatment steps in the current guidelines, those
symptoms often reflect non-asthma factors relating to the
patient’s psychological status, and can affect the physician’s
judgement.23 In such cases, rather than increasing the
current asthma treatments, other therapeutic choices may
be considered. Therefore, to manage patients effectively in
routine practice as well as to improve their asthma
outcomes, the patient’s psychological status should be
considered.
Although some promising results were obtained, the role
of psychological interventions in asthma has not been
established.24 Since it is apparent that the psychological
status affects both patient symptoms and the asthma
management methods used by physicians, it is recom-
mended that some effective psychological interventions be
investigated in well-controlled clinical trials.
Changes in anxiety and depression were moderately and
significantly correlated to changes in the health status. In
cross-sectional studies, it is often reported that the
psychological status contributes to the health status in
asthma.1 Herein we demonstrated that, from a longitudinal
viewpoint, this significant relationship between the psycho-
logical status and the health status holds true. In addition,
the changes in anxiety and depression were not significantly
correlated to changes in physiological markers, as a cross-
sectional study demonstrated a non-significant relationship
between the psychological status and physiological mea-
surements.3 Therefore, it is important to measure the
psychological status longitudinally and separately from
conventional measurements such as FEV1, PEF or AHR, not
to miss any psychological deterioration which can relate to a
health status impairment.
Most patients in the present study had a clinically normal
psychological status as judged from their baseline HADS
scores. However, patients with worse HADS scores at
baseline showed subsequently steeper deteriorations over
time. Therefore, psychological status evaluations in patients
with asthma using the HADS are useful in predicting future
asthma worsening, even though these patients were initially
within normal limits. Furthermore, we found that changes in
anxiety and depression correlated strongly with one
another. This indicates that patients who showed a
deterioration in one of the two subscales of the HADS might
also show an impairment in another subscale. Therefore,
caution is required as those patients may be psychologically
at risk.
Asthma and COPD are among the two most common
chronic respiratory disorders in the world, and similarities
versus differences between these two conditions have been
discussed from various viewpoints.25,26 We also previously
followed patient reported outcomes and physiological ones
in patients with COPD over 5 years,10,11 and reported that
both anxiety and depression from the HADS worsened
significantly over time.11 Therefore, we found a clear
difference in the progression of psychological disturbances
between asthma and COPD.In the present study, we observed that fewer patients at
baseline had clinically relevant levels of anxiety and
depression than other studies. First, the psychological status
can differ according to the patient populations included in
the analysis or their social status.23 For example, in one
study,3 6% of the patients had anxiety and 1% had
depression, which is similar to our study; however, in
another study,23 the same findings were 30% and 9%,
respectively. Second, in our study, all patients were treated
stably for over 6 months for their asthma based on the
guideline. Therefore, any psychological problems due to
asthma instability may have been suppressed.
The present sample size was a small one from a single
university hospital with relatively high dropout rates and
low never smokers rates. This might have limited any
generalization of the results. Regarding dropping out in
asthma trials, the reasons for this are complex27 and it is
difficult to understand the actual causes for withdrawal
because patients do not always state their real reasons, and
stuff interpretation may vary greatly in accuracy.28 In the
present study, we used the MAR approach in the mixed
effect model analysis; however, as one limitation, we should
have compared the two approaches of the MAR and not
missing at random mechanisms to investigate any potential
bias caused by introducing the MAR mechanism into the
analysis, as discussed elsewhere.8
In conclusion, with maintenance therapy using inhaled
corticosteroids, the psychological status remained clinically
stable over 5 years in patients with asthma. In addition, the
changes in the psychological status were found to be
significantly correlated to changes in the health status,
but not with physiological measurements. Although a poor
psychological status has been reported to produce worse
asthma outcomes, the present study shows that baseline
HADS scores are useful indicators in detecting patients
whose psychological status may subsequently deteriorate
over time. Therefore, psychological assessments are re-
commended in managing patients with asthma.References
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